Equinor ASA
Equinor ASA: proposal on capital reduction from the company’s board of directors
Equinor ASA: proposal on capital reduction from the company’s board of directors
The board of directors of Equinor ASA (OSE: EQNR, NYSE: EQNR) has today decided to propose to the general meeting of the company that the company’s share capital is reduced through cancellation of own shares and redemption of shares belonging to the Norwegian State. The proposal is made as a result of the company having acquired own shares pursuant to the authorization for share buy-back granted by the annual general meeting of the company in May 2024.
The proposal entails that the company's share capital shall be reduced by NOK 589,934,295 from NOK 6,981,953,075.00 to NOK 6,392,018,780.00, through cancellation and redemption of a total of 235,973,718 shares. Notice of the general meeting of the company which will attend to the board’s proposal will be announced separately at a later stage.
This information is subject to the disclosure requirements pursuant to Euronext Oslo Børs Rulebook II section 4.2.4 and Section 5-12 of the Norwegian Securities Trading Act.
Contact persons:
Investor relations:
Bård Glad Pedersen, Senior vice president Investor Relations,
+47 918 01 791
Media relations:
Sissel Rinde, Vice president Media Relations,
+47 412 60 584
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
798 Art District26.4.2025 14:44:55 CEST | Press release
798 Art District and Beijing International Film Festival Jointly Launch “Art Lights the Screen” – A Cultural Feast of Film and Art
Atlantic Petroleum P/F26.4.2025 14:32:40 CEST | Press release
Summons for the Annual General Meeting of P/F Atlantic Petroleum
Financière de Tubize SA26.4.2025 08:00:00 CEST | Press release
Financière de Tubize - Dividend approval
MoonLake Immunotherapeutics AG25.4.2025 22:05:00 CEST | Press release
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
T-knife Therapeutics25.4.2025 19:00:00 CEST | Press release
T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom